Home › Research › Risk genes beyond APOE
Combating cognitive decline in a rat model of Alzheimer’s disease: The role of high-intensity interval training and cannabidiol administration in modulating microRNA-124, BACE1, and nestin
Mohammad Reza Kordi, Amir Reza Kooshan, Seyed Pouya Jafari-Hokmabadi, Abbas Ali Gaeini, Amir Mohammad Zobeydi. Current Journal of Neurology, 2026-05-30
Topic: Brain proteins, microglia and lab models
Plain-language summary
HIIT alone and in combination with CBD treatment significantly improved cognitive impairment induced by AD. Moreover, both treatments significantly reduced BACE1 protein expression and increased nestin protein expression in AD rats. However, despite decreased miRNA-124 expression levels in the AD group in comparison with the CNT group, HIIT and CBD administration did not alter miRNA-124 expression levels in other groups. The findings can contribute to a higher understanding of the beneficial effects of HIIT combined with CBD administration in mitigating AD-induced cognitive impairment by reducing BACE1 protein expression and increasing nestin protein expression.
What this study adds
Evidence grade: Low
In a rat model of Alzheimer's disease, high-intensity interval training alone and combined with cannabidiol improved cognitive impairment and reduced BACE1 while increasing nestin, but neither treatment changed miRNA-124 levels. These are animal findings and do not establish a treatment for people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kordi, M. R., Kooshan, A. R., Jafari-Hokmabadi, S. P., Gaeini, A. A., & Zobeydi, A. M. (2026). Combating cognitive decline in a rat model of Alzheimer’s disease: The role of high-intensity interval training and cannabidiol administration in modulating microRNA-124, BACE1, and nestin. Current Journal of Neurology. https://doi.org/10.18502/cjn.v24i3.21601
Vancouver
Kordi MR, Kooshan AR, Jafari-Hokmabadi SP, Gaeini AA, Zobeydi AM. Combating cognitive decline in a rat model of Alzheimer’s disease: The role of high-intensity interval training and cannabidiol administration in modulating microRNA-124, BACE1, and nestin. Current Journal of Neurology. 2026. doi:10.18502/cjn.v24i3.21601. PMID: 42634764.
BibTeX
@article{kordi2026-42634764,
author = {Kordi, Mohammad Reza and Kooshan, Amir Reza and Jafari-Hokmabadi, Seyed Pouya and Gaeini, Abbas Ali and Zobeydi, Amir Mohammad},
title = {{Combating cognitive decline in a rat model of Alzheimer’s disease: The role of high-intensity interval training and cannabidiol administration in modulating microRNA-124, BACE1, and nestin}},
journal = {Current Journal of Neurology},
year = {2026},
doi = {10.18502/cjn.v24i3.21601},
pmid = {42634764},
url = {https://doi.org/10.18502/cjn.v24i3.21601}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- HIIT alone and in combination with CBD treatment significantly improved cognitive impairment induced by AD.
- Moreover, both treatments significantly reduced BACE1 protein expression and increased nestin protein expression in AD rats.
- However, despite decreased miRNA-124 expression levels in the AD group in comparison with the CNT group, HIIT and CBD administration did not alter miRNA-124 expression levels in other groups.
- The findings can contribute to a higher understanding of the beneficial effects of HIIT combined with CBD administration in mitigating AD-induced cognitive impairment by reducing BACE1 protein expression and increasing nestin protein expression.
Why it matters
In a rat model of Alzheimer's disease, high-intensity interval training alone and combined with cannabidiol improved cognitive impairment and reduced BACE1 while increasing nestin, but neither treatment changed miRNA-124 levels. These are animal findings and do not establish a treatment for people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 30/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 29 of the 96 points we could judge it on, which is 30 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current Journal of Neurology) |
| Journal's citation record | 0 / 4 | Current Journal of Neurology: journal h-index 16 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “rat”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Amir Mohammad Zobeydi holds only 7 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Ruhr University Bochum: institution h-index 704 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42634764) |
| Free to read | 2 / 2 | Free to read |
| Points | 29 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 96 points we could judge it on is 30 out of 100. |
| Total | 30 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.18502/cjn.v24i3.21601
- PubMed: 42634764
- Original source →
- Free full text: Current Journal of Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk genes beyond APOE from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.